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Abstract
Background: Pre-eclampsia and eclampsia are major causes of maternal morbidity and mortality. Magnesium
sulphate is accepted as the anticonvulsant of choice in these conditions and is present on the WHO essential
medicines list and the Indian National List of Essential Medicines, 2015. Despite this, magnesium sulphate is not
widely used in India for pre-eclampsia and eclampsia. In addition to other factors, lack of availability may be a
reason for sub-optimal usage. This study was undertaken to assess the availability and use of magnesium sulphate
at public and private health care facilities in two districts of North Karnataka, India.
Methods: A facility assessment survey was undertaken as part of the Community Level Interventions for Pre-eclampsia
(CLIP) Feasibility Study which was undertaken prior to the CLIP Trials (NCT01911494). This study was undertaken in 12
areas of Belagavi and Bagalkote districts of North Karnataka, India and included a survey of 88 facilities. Data were
collected in all facilities by interviewing the health care providers and analysed using Excel.
Results: Of the 88 facilities, 28 were public, and 60 were private. In the public facilities, magnesium sulphate was
available in six out of 10 Primary Health Centres (60%), in all eight taluka (sub-district) hospitals (100%), five of eight
community health centres (63%) and both district hospitals (100%). Fifty-five of 60 private facilities (92%) reported
availability of magnesium sulphate.
Stock outs were reported in six facilities in the preceding six months – five public and one private. Twenty-five percent
weight/volume and 50% weight/volume concentration formulations were available variably across the public and
private facilities. Sixty-eight facilities (77%) used the drug for severe pre-eclampsia and 12 facilities (13.6%) did not use
the drug even for eclampsia. Varied dosing schedules were reported from facility to facility.
(Continued on next page)
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Conclusions: Poor availability of magnesium sulphate was identified in many facilities, and stock outs in some.
Individual differences in usage were identified. Ensuring a reliable supply of magnesium sulphate, standard
formulations and recommendations of dosage schedules and training may help improve use; and decrease morbidity
and mortality due to pre-eclampsia/ eclampsia.
Trial registration: The CLIP trial was registered with ClinicalTrials.gov (NCT01911494).
Keywords: Magnesium Sulphate, Availability, Health care facilities, Pre-eclampsia, Eclampsia, Karnataka, India

Background
Pre-eclampsia and eclampsia are a leading cause of maternal mortality, contributing to 14% of maternal deaths
worldwide [1]. Every day approximately 830 women die as
a result of pregnancy complications all over the world and
99% of these deaths occur in developing countries [2]. In
2015, globally there were 303,000 maternal deaths; and
45,000 (about 15%) of these were in India [3]. India has
fallen short of achieving the Millennium Development
Goal of reducing the national maternal mortality ratio
(MMR) to 109 by 2015. Despite a substantial reduction in
maternal deaths, the MMR of India stood at 174 per
100,000 livebirths in 2015 [3]. It is now necessary to focus
on the newly adopted Sustainable Development Goals targeted to reduce the global MMR to 70.
Interventions targeting maternal deaths need to address pre-eclampsia and eclampsia as it is the second
leading direct cause of maternal mortality, second only
to haemorrhage [1]. Also, these conditions can result in
major morbidity and residual complications which affect
the quality of life of the woman and her family and significant economic burden.
Magnesium sulphate is the drug of choice for the prevention and treatment for the seizures of eclampsia [4].
The Magpie trial established that women receiving magnesium sulphate versus placebo were 58% less likely to
have convulsions and it also led to a decreased risk of
placental abruption. Follow-up studies of the participants of the Magpie trial and their babies showed no
long-term harm or benefit to either [5–7]. A systematic
review of the Cochrane database in 2010 found that
magnesium sulphate is better than phenytoin and nimodepine in preventing convulsions and results in a nonsignificant decrease in maternal deaths [8]. Studies have
also proven that it prevents convulsions better when
compared to the other treatment regimens for eclampsia
like the lytic cocktail regimen and diazepam [9, 10].
The World Health Organization’s (WHO) list of essential medicines and the Indian National List of Essential
Medicines (NLEM) 2015 identify magnesium sulphate as
an essential commodity for maternal health [11, 12]. It is
interesting to note that the NLEM lists it under S and T
categories which means that it should be available at
secondary and tertiary facilities, when in contrast, the

Indian Public Health Standards (IPHS) Revised Guidelines 2012, specifically the IPHS guidelines for primary
health centres (PHCs), state that magnesium sulphate
should be present in the labour room in the PHCs [13].
The antidote to magnesium sulphate, calcium gluconate
is listed on the WHO list of essential medicines and also
features on the NLEM 2015 under categories P, S and T,
implying that it should be present at the primary, secondary and tertiary levels.
The guidelines for skilled birth attendants in India recommend that magnesium sulphate be administered in
cases of severe pre-eclampsia and eclampsia prior to referral [14]. These guidelines are meant to guide the functioning of Staff Nurses (providing services at the primary
health centres and higher facilities), Auxiliary Nurse
Midwives (ANMs; providing services at the subcenters)
and Lady Health Visitors (LHVs) who are in a supervisory capacity for the ANMs. The guidelines also recommend that magnesium sulphate be present in the kit for
home delivery and specify that the skilled birth attendants are permitted to use magnesium sulphate for both
eclampsia and severe pre-eclampsia, and that arrangements for immediate referral should then be made [14].
Providing the loading dose of magnesium sulphate will
stabilize a woman for safe transport to a facility, which is
better equipped to handle these complications. Despite
all the recommendations, use of magnesium sulphate is
not universal [15].
There may be many reasons for the sub-optimal use of
magnesium sulphate, such as a lack of knowledge, lack
of familiarity with the drug, the large volume of the injection, apprehension of complications, widely varied
doses and dosage schedules that may be confusing;
among others [15]. Though there are standard regimens
described in obstetric textbooks, there are concerns that
the dose may be too large for the smaller built Indian
woman. Hence several modified regimens are followed
in practice [16–19]. In addition to this, magnesium
sulphate may not be readily available in all settings [15].
We undertook an assessment of health facilities in two
districts of North Karnataka to note how they were
equipped in handling obstetric and neonatal care. In this
study, we report the availability and use of magnesium
sulphate at the facilities assessed.
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Methods
This study was carried out in Belagavi and Bagalkote districts of North Karnataka. Karnataka is a south Indian
state with a MMR of 133/100,000 livebirths in 2011-2013
as per the Sample Registration System. There are vast differences in health infrastructure and service delivery in
the districts of northern and southern Karnataka [20]. The
CLIP Feasibility Study was undertaken in 12 areas of
Belagavi and Bagalkote districts (six in each district) [21].
The two adjoining districts are quite dissimilar, with
poorer health indices in Bagalkote district [20]. Before the
CLIP Trial (NCT01911494), the 12-month Feasibility
Study was undertaken to assess the context, and identify
any potential barriers and facilitators to the implementation of CLIP.
As a part of the CLIP Feasibility Study, facility assessment was undertaken to determine the capacity of facilities in the study area in the provision of maternal and
newborn health services, with a focus on care of women
with pre-eclampsia and eclampsia. Medical officers, in
charge of provision of care at primary health centres
(PHC), were asked to identify and list the health care
facilities that women in their area frequent. In total, 88
facilities were identified. The survey of the facilities was
undertaken between April and August 2013.
The survey was carried out by trained medical professionals from the research team from the same region,
who underwent training for a day in the approach necessary for data collection. Those conducting assessments
were predominantly clinicians; this provided important
background knowledge for successful completion of the
forms. The primary obstetric care provider at each facility
was approached for a one-on-one interview to provide necessary information, with some fields being completed
with inputs from pediatric care providers, laboratory technicians and review of institutional records. Consent was
obtained from the respondents before proceeding.
A pre-structured questionnaire was used to document
the responses received. The questionnaire recorded preliminary data about the name of the facility, location,
person responding to the questionnaire, contact numbers, type of facility, usual place of referral, catchment
area and population served. It also included the number
of beds, availability of intensive care units, a comprehensive description of the available personnel, equipment,
drugs and services, costs, transportation to and from the
facility, access to blood transfusion, and the volume of
patients. Questions pertaining to additional training in
maternal and neonatal care were included in the format,
as were those related to existence and use of facility
guidelines for the management of hypertensive disorders
of pregnancy. Questions regarding hypertension in
pregnancy, criteria used for diagnosis of mild and severe
pre-eclampsia, antihypertensive treatment, and use of
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magnesium sulphate were also asked. The majority of
the questions in the survey tool were close-ended
though a few questions requested detailed answering.
Data were directly recorded on to hard copies of the
questionnaire at the time of the interview. The questionnaire used in this study has been added as an appendix
to this paper (Additional file 1).
All data were keyed into a locally developed Access
database. The data were cleaned prior to analysis. Frequencies were run on all quantitative fields providing
totals, means and standard deviations.
This study was approved by ethics review committees
at the University of British Columbia, Vancouver Canada
(H12-00132) and KLE University, Belgaum (Ref No:
MDC/IECHSR/2013-14/A-28) India.

Results
Of the 88 facilities, 28 were public and 60 were private.
Table 1 provides a description of the facilities surveyed.
The facilities assessed included 8 Community Health
Centres (CHC) out of the total 24 in the two districts
(33%) as reported by the Health Management Information System of the Ministry of health and Family welfare;
8 taluka hospitals out of the total 14 (57%), and both
the district hospitals (100%). The total number of private
obstetric facilities in the two districts could not be ascertained to determine the proportion assessed.
All health care facilities with magnesium sulphate at
the time of assessment also reported access to the drug
in the labour room. Data regarding stock outs in the
preceding 6 months were collected. While the majority
of the healthcare facilities did not report any stock outs,
five public facilities did report stock outs at the time of
assessment, one reporting multiple instances in the preceding 6 months. One private facility reported a stock
out. One CHC and one private hospital reported having
no availability of magnesium sulphate at any time and
hence there was no response to whether stock outs occurred. One PHC medical officer reported that they did
not wait for replenishment of stock through the government supply since it was not streamlined, and they
bought the necessary supply through funds allocated to
the PHC. Table 1 shows the different categories of health
facilities surveyed, availability of magnesium sulphate at
the time of assessment and stock outs in the preceding
6 months.
The availability of other essential obstetric medications
was ascertained. There were differences in availability,
with some facilities reporting availability of one type of a
drug in a category versus another (for example betamethasone/dexamethasone, different antihypertensives
etc.) and some reporting availability of all the drugs. All
facilities reported the availability of uterotonics, oxytocin
in particular.
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Table 1 Facilities assessed, the availability of magnesium sulphate at assessment and stock outs in preceding 6 months
Type of facility
Public facilities

Belagavi district

Bagalkote District

Total

N

A

S

N

A

S

N

A

S

Primary Health Centre

9

5

2

1

1

0

10

6

2

Community Health Centre

4

3

0

4

2

2

8

5

2

Taluka Hospital

4

4

0

4

4

1

8

8

1

District Hospital

1

1

0

1

1

0

2

2

0

Private facilities

39

35

0

21

20

1

60

55

1

All facilities

57

48

2

31

28

4

88

76

6

N Number assessed
A Magnesium sulphate available during survey
S Stock outs of magnesium sulphate in preceding six moths

Regarding the formulation of magnesium sulphate
available, responses were collected from 29 facilities with
magnesium sulphate at the time of assessment. Of these,
22 (6 public and 16 private) facilities reported carrying a
concentration of 50% weight /volume (w/v), three (one
public and 2 private) reported having 25% w/v and four
(one public and 3 private) reported having both
strengths available. All ampoules were of 2 ml.
Information on practices related to magnesium
sulphate usage was collected, including the use of magnesium sulphate in the management of severe preeclampsia (Table 2). Health care professionals from 68
facilities responded that they did use it for management
of severe pre-eclampsia, and notably this included five
PHCs. Thirty-two providers reported differential dosing
schedules for severe pre-eclampsia as opposed to
eclampsia with differences in both the route and the
dosage of magnesium sulphate used. Seventeen of the 68
providers reported that they did not provide a maintenance dose in cases of severe pre-eclampsia. One private
practitioner reported maintenance therapy with phenytoin after the loading dose of magnesium sulphate for
pre-eclampsia. All the PHCs and two private hospitals
using magnesium sulphate reported immediate referral

Table 2 Facilities using magnesium sulphate for management
of severe pre-eclampsia
Use of MgSO4 for severe pre-eclampsia
Yes

No

Never used MgSO4 for even eclampsia

Public

17

Private

51

Total

68

Public

4

Private

4

Total

8

Public

7

Private

5

Total

12

of patients with severe pre-eclampsia and eclampsia,
without waiting for the maintenance dose.
When asked about alternative treatment strategies in
eclampsia in place of magnesium sulphate amongst
those using the drug, the majority of the providers mentioned use of injection diazepam or phenytoin, but only
in cases where magnesium sulphate failed. Only one
provider mentioned that maintenance treatment was
routinely provided with phenytoin.
A notable observation was that 12 providers did not use
magnesium sulphate even for eclampsia. This included 4
PHCs, 3 CHCs and 5 private facilities. Three of these 12
facilities did report availability of magnesium sulphate at
the time of assessment. Four of the 12 providers mentioned the use of injectable diazepam for eclampsia.
Varied dosage schedules were reported, with 25 (3 public
and 22 private) of 68 providers reporting using standard
Pritchard or Zuspan regimens for severe pre-eclampsia,
and 44 (13 public and 31 private) of 76 reporting use of
standard Pritchard or Zuspan regimens for eclampsia. The
dosages reported were very varied, with most providers
who were not using standard regimens resorted to lower
doses, some up to half of the Pritchard and Zuspan regimens. One obstetrician at a private facility reported the use
of 2 g intramuscularly (IM) as the loading dose and 2 g IM
twice a day as the maintenance dose for eclampsia. There
were also some unusual responses like 100 mg intravenously (IV) every 8 h; and 25% IM. The respondents in these
cases were not obstetricians by qualification but were still
the primary obstetric providers in that facility. Interestingly, 10 providers said they determine the loading and
maintenance doses based on the patient’s condition.
The availability of calcium gluconate, the antidote to
magnesium sulphate was asked for. Calcium gluconate
was not available in 12 facilities, including 8 which reported availability of magnesium sulphate (Table 3).

Discussion
Despite the well-established superiority of magnesium
sulphate in the management of severe pre-eclampsia and
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Table 3 Non-availability of calcium gluconate by type of facility
Type of facility

Calcium gluconate
not available

Calcium gluconate not
available but magnesium
sulphate available

PHC

2

0

Taluka Hospital

1

1

CHC

2

1

Private

7

6

eclampsia, it continues to be used sub-optimally. In our
study, non-availability of magnesium sulphate was identified at several facilities. In addition, stock outs were experienced at five public facilities and one private secondary
facility in the preceding 6 months but in none of the tertiary health facilities. Calcium gluconate was available in
86% of the facilities assessed but 8 facilities with availability
of magnesium sulphate did not have calcium gluconate.
It was found that the health facilities had differing
strengths of magnesium sulphate available, some reporting both 25% w/v and 50% w/v. The facilities reported
varying dosage schedules, some of which may not have
the required stabilizing action and may not optimally
benefit the patient.
The availability of magnesium sulphate seemed to be
similar across the two districts in this study. However,
there were more stock outs in the preceding 6 months in
Bagalkote when compared to Belagavi. Also, the stock
outs were in the secondary level facilities in Bagalkote as
opposed to primary health centres in Belagavi. Availability
and use of magnesium sulphate across all levels of healthcare is important for ensuring favourable outcomes.
The fact that other essential medications for obstetric
health were available at the facility and only magnesium
sulphate seemed to be missing, points to the fact that the
supply chain is generally functioning. Due importance is
not given to make magnesium sulphate available. The providers at the public facilities do have funds to procure the
drug through other suppliers but have to maintain a watch
on the stock to see that the supply is uninterrupted.
The facilities assessed in this study were the ones most
often used for delivery and it would be expected that
these health facilities would have better logistics than
those not providing regular obstetric services. It is
probable that this assessment does not represent all
facilities in the region, and that others may have poorer
availability and use of magnesium sulphate. The strength
of this study is that researchers were trained medical
professionals and hence had a better contextualization of
the study. A limitation of this study is that the health
care providers self-reported the availability and use of
magnesium sulphate in the facilities they served. It was
not physically ascertained as to how many ampoules
were present, whether the ampoules were within the
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date of expiry, and whether magnesium sulphate was
used in the manner reported. Though the researchers
encouraged practitioners to report actual practices, the
fact that the researchers were fellow clinicians may have
induced a bias to report favourably.
A study assessing 279 health care facilities in eight districts of northern Karnataka in 2010 revealed that magnesium sulphate was available in only 18% of PHCs, 48% of
higher public facilities and 70% of private facilities [22]. In
comparison, the present study found that 60% of PHCs,
72% of higher public facilities and 92% private facilities reported availability of magnesium sulphate at the time of
assessment. This difference may be because we selectively
sampled facilities providing regular obstetric services.
A study from Maharashtra state, India assessing 44
secondary and tertiary public health facilities in 20092010 found that 61% of facilities had no stock of magnesium sulphate, with the stock-out position ranging from
3 months to 3 years. The researchers ascertained
whether they had the minimum of 50 ampoules recommended in the guidelines for CHCs and found that 20%
facilities had less than the minimum recommended and
also that 11.4% of the assessed facilities did not have
enough ampoules to even provide the first dose to a single woman [23]. The stock outs in the present study
were much fewer, with only five of 28 public facilities
(18%) reporting stock outs in the 6 months before the
survey, again perhaps due to the convenience sampling
used in this study. The quantity of drug available was
not assessed in this study.
Another study done in Nagpur, Maharashtra concluded that though senior gynaecologists favoured the
use of magnesium sulphate especially prior to referral,
its use was limited due to lack of institutional policies
on dosing, timing, indications and also due to limited
availability, especially in tertiary care centres [24]. In the
present study too, it was found that health care providers did not have uniform policies on indications and
dosing, even when the drug was available.
A 2010 WHO study that assessed emergency obstetric
care across six developing countries, including India,
found that only 53% of facilities with basic emergency
obstetric care (BEmOC) and 86% of facilities with
comprehensive emergency obstetric care (CEmOC) had
IM/IV anticonvulsants [25]. The study also indicated
that public facilities were unable to provide emergency
obstetric care due to lack of good management systems
to ensure continuous availability of drugs and supplies
and emphasized the importance of strengthening the
chain for procurement and distribution of basic drugs
and equipment; and to improve skills of the providers to
ensure at least coverage of BEmOC [25]. In the present
study, in addition to the issues about availability of
magnesium sulphate, we found that providers at 12

Katageri et al. Reproductive Health 2018, 15(Suppl 1):91

facilities did not administer magnesium sulphate even
for eclampsia despite three of these facilities reporting
availability. This emphasizes the need for knowledge and
skill enhancement activities to improve usage practices
in addition to improving the supply chain.
Even though the guidelines for skilled birth attendants
[14] recommend that the ANM should administer magnesium sulphate for severe pre-eclampsia prior to referral, the medical officers (who are qualified physicians) of
five of the PHCs stated that they did not use magnesium
sulphate for severe pre-eclampsia and despite availability
of magnesium sulphate, usage for even eclampsia was
not universal. Familiarising health care professionals
with treatment recommendations, and building their
capacity and confidence could go a long way in optimizing the administration of magnesium sulphate.
There are standard regimens for the use of magnesium
sulphate, Pritchard, Zuspan and Sibai; as well as, many
other dosage schedules [16–19]. A systematic review of
the studies evaluating these regimens in low- and
middle-income countries was unable to establish the superiority of any regimen and the lowest effective dose is
not agreed upon [26]. It was found in four studies that
the administration of the loading dose only was as effective as loading plus maintenance [26]. The varied dosage schedules, however, confuse practitioners who may
not be familiar with magnesium sulphate. The strength
of the drug formulation also varies and achieving the
correct dilution for IV administration may be prone to
error and confusion [27]. In the present study, we did
find that the health facilities had differing strengths
available and used many differing dosing schedules. It is
important that there be a standard formulation and requirement for adherence to standard dosing schedules
to increase appropriate use and optimize action.
Magnesium sulphate toxicity occurs very infrequently if
guidelines are followed during administration. In the event
that it does occur, serious complications can usually be
averted by skipping the next dose. However, in rare instances, administration of calcium gluconate is required
and may be lifesaving [28]. Hence, care should be taken to
ensure availability and train the providers in appropriate
use. A study in Lucknow, India in 2014 found that only
33.3% Bal Mahila Chikitsalayas (health care facilities for
women and children) which serve as first referral units
had availability of calcium gluconate [29]. In our study,
availability was found to be better with 86% facilities
reporting the drug at the time of assessment.
The Indian guidelines are conflicting, with the NLEM
recommending magnesium sulphate availability in the
secondary and tertiary facilities, the IPHS guidelines for
PHCs recommending availability in the labour room of
the PHCs; and the guidelines for skilled birth attendants
recommending that it be available at the sub-center and
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even in the home delivery kits [12–14]. Conflicting
recommendations of this nature need to be rectified to
ensure enhanced usage.
The first step to encourage enhanced magnesium
sulphate use is that it should be available at all health care
facilities providing for obstetric patients, without any
stock-outs. It is also essential to increase the providers’
comfort and confidence in using this drug. All levels of
obstetric care providers need to be re-trained periodically
in the benefits and use of magnesium sulphate.
Observing the appropriate use of magnesium sulphate
by senior obstetric providers may enhance uptake by the
other health care providers like resident doctors, ANMs
and staff nurses. However, they need to be exposed to
the use of this drug in a consistent manner. Standardizing the strength and dosing schedules is essential; and
guidelines for referral should be developed and enforced.
Identification of non-compliant facilities could be done
by tracking referrals. Ascertaining the cause for deviation with corrective action and refresher training could
be a solution to increase appropriate use. Cases of
eclampsia could also serve as triggers for evaluating the
delays and deficiencies in the health system and identifying and implementing potential remedial action.
Future research could focus on the reasons for hesitancy for use of magnesium sulphate by obstetric providers so as to inform the health system administrators
about the steps necessary to increase usage.

Conclusion
This study found that there were deficiencies in the
availability of magnesium sulphate in health care facilities that routinely cared for obstetric patients in north
Karnataka. The public health facilities faced stock outs
though they could procure the drug through funds allocated to them. This shows a poor chain of coordination
between the suppliers, distributors and the users.
Addressing contradictions in the Indian national
guidelines regarding place of availability, indications for
use and cadre of health care professionals permitted to
use magnesium sulphate is of prime importance.
The indications for which magnesium sulphate was used
and the strength of drug available varied across facilities of
the same type. Standardization of the drug formulation
and familiarization with guidelines is important to ensure
optimal use of magnesium sulphate. In addition, identification of the factors preventing use; and trainings and refresher trainings to address these issues would increase
appropriate usage of magnesium sulphate.
Despite a major reduction in the maternal mortality,
the Millennium Development Goals of 2015 were not
met in India; nevertheless, positive action in this regard
could bring us closer to attaining the Sustainable
Development Goals by 2030.
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